Business Context and Reporting Period
Company: MiNK Therapeutics, Inc. (INKT)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2026
Business Overview: MiNK is a clinical-stage biopharmaceutical company developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies for cancer and immune-mediated diseases. The company operates as a single segment and is classified as an emerging growth company and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(2,742,368) | $(2,766,697) |
| Diluted EPS | $(0.57) | $(0.70) |
| Operating Cash Flow | $(1,732,597) | $(1,340,876) |
| Cash and Equivalents (End of Period) | $9,525,676 | $3,234,899 |
| Total Assets | $10,376,972 | $14,238,842 (Dec 31, 2025) |
| Accumulated Deficit | $(159,418,363) | $(146,948,432) (Mar 31, 2025) |
Debt and Liquidity: As of March 31, 2026, the company had no outstanding related party notes (repaid in January 2026). Current liabilities totaled $7.3 million, including $2.6 million in other current liabilities related to a government advance dispute. The company maintains a stockholders' deficit of $12.7 million.
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased slightly to $2.9 million in Q1 2026 from $2.7 million in Q1 2025.
- Research & Development (R&D): Decreased 5% to $1.2 million, driven by lower personnel costs and timing of clinical activities.
- General & Administrative (G&A): Increased 32% to $1.7 million, primarily due to higher share-based compensation and professional fees.
- Related Party Note: The company repaid a $5.0 million convertible promissory note to Agenus in full during January 2026. This resulted in a $5.0 million cash outflow in financing activities and eliminated the associated interest expense and fair value adjustments seen in the prior year.
- Equity Financing: The company raised approximately $3.0 million in net proceeds from the sale of 193,060 shares under its At-the-Market (ATM) sales agreement in Q1 2026. No equity sales occurred in Q1 2025.
- Other Income: Other income improved from a net expense of $79,527 in Q1 2025 to income of $58,585 in Q1 2026, largely due to foreign currency translation gains offsetting prior period losses.
Outlook, Risks, and Management Commentary
Going Concern: Management has disclosed substantial doubt about the company's ability to continue as a going concern for one year from the filing date. While cash on hand ($9.5 million) plus subsequent ATM proceeds ($150,000) and anticipated funding are believed sufficient for over 12 months, the completion of anticipated funding is not entirely within the company's control.
Capital Resources: The company continues to rely on equity financing, strategic partnerships, and non-dilutive grants. Approximately $31.8 million remains available under the current ATM agreement as of May 13, 2026.
Development Pipeline:
- agenT-797: Lead native iNKT cell therapy. A randomized Phase 2 trial for severe pneumonia/acute respiratory failure is ongoing in Ukraine with U.S. sites enrolling; preliminary data expected in H2 2026. Oncology trials continue to show durable responses in refractory solid tumors.
- Engineered Programs: MiNK-215 (FAP-CAR-iNKT) and MiNK-413 (BCMA-CAR-iNKT) are in preclinical/IND-enabling stages.
Risks and Contingencies:
- Legal: A default judgment exists regarding a $2.4 million advance from the Belgium Walloon Region Government, classified as a current liability.
- Personnel: The Principal Accounting Officer, Austin Charette, announced resignation effective May 29, 2026.
- Regulatory: As with all clinical-stage biotechs, there is significant uncertainty regarding the timing and cost of regulatory approvals.
Investor Verification Checklist
- Liquidity Runway: Verify the status of "anticipated funding" mentioned in the going concern disclosure to confirm the 12-month cash runway.
- Walloon Region Liability: Review the status of the $2.4 million dispute with the Belgium Walloon Region Government and any potential repayment obligations.
- ATM Utilization: Monitor the pace of share sales under the remaining $31.8 million ATM capacity and potential dilution impact.
- Clinical Milestones: Track enrollment and preliminary data release for the Phase 2 agenT-797 trial in acute respiratory failure (expected H2 2026).
- Accounting Transition: Confirm the appointment of a new Principal Accounting Officer following the May 2026 resignation.